Stage IV Colorectal Cancer AJCC v7
Information
- Disease name
- Stage IV Colorectal Cancer AJCC v7
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03087071 | Active, not recruiting | Phase 2 | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | December 29, 2017 | January 31, 2025 |
| NCT03337087 | Active, not recruiting | Phase 1/Phase 2 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | November 2, 2018 | August 9, 2025 |
| NCT01638533 | Active, not recruiting | Phase 1 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | June 12, 2012 | March 5, 2025 |
| NCT02738606 | Active, not recruiting | Phase 2 | Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery | May 25, 2016 | December 31, 2025 |
| NCT02873195 | Active, not recruiting | Phase 2 | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | July 7, 2017 | July 1, 2024 |
| NCT02888743 | Active, not recruiting | Phase 2 | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | August 14, 2017 | January 2, 2025 |
| NCT01787500 | Active, not recruiting | Phase 1 | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | February 15, 2013 | March 31, 2026 |
| NCT03317119 | Completed | Phase 1 | Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery | April 11, 2018 | July 14, 2023 |
| NCT02754856 | Completed | Phase 1 | Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery | July 28, 2016 | January 30, 2023 |
| NCT02292758 | Completed | Phase 2 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | December 12, 2014 | September 27, 2019 |
| NCT02368886 | Completed | Phase 2 | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | March 27, 2015 | March 2, 2023 |
| NCT03403634 | Completed | Phase 2 | Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | April 19, 2018 | August 29, 2021 |
| NCT03396926 | Completed | Phase 2 | Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery | April 18, 2018 | January 30, 2024 |
| NCT05334069 | Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | August 1, 2022 | February 2025 | |
| NCT02600949 | Recruiting | Phase 1 | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | May 11, 2016 | May 31, 2025 |
| NCT02997228 | Recruiting | Phase 3 | Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study | January 19, 2018 | November 30, 2024 |
| NCT01365169 | Recruiting | N/A | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | May 25, 2011 | June 30, 2027 |
| NCT02757391 | Terminated | Phase 1 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | August 9, 2019 | October 2, 2020 |
| NCT03300609 | Terminated | Phase 3 | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab | February 27, 2018 | October 3, 2019 |